India, May 22 -- This week's biotech landscape saw regulatory approvals across the U.S., Canada, and China, alongside collaborations, acquisitions, program halts, and positive data readouts spanning multiple therapeutic areas, including severely calcified coronary artery disease, Wilson disease, and alpha-1 antitrypsin deficiency. Let's unpack the specifics.
FDA Approvals and Rejections
HUTCHMED, Innovent Win NMPA Approval for ELUNATE-TYVYT Combo in Advanced Kidney Cancer
HUTCHMED (HCM) and Innovent Biologics, Inc (HKEX:1801) received NMPA approval in China for the combination of ELUNATE (fruquintinib) and TYVYT (sintilimab injection) to treat patients with locally advanced or metastatic renal cell carcinoma (RCC) who previously failed V...